Research Article
Prognostic Impact of Lymphoid Enhancer Factor 1 Expression and Serum Galectin.3 in Egyptian AML Patients
Table 3
The association between LEF1, Galectin-3 and treatment outcome.
| | LEF1 | | | Galectine.3 | | | | Low, | High, | <5.6, | ≥5.6, |
| | Time to 1st CR | 43.5 ± 13.23 | 34.84 ± 15.71 | −2.1 | 0.036 | 29.42 ± 10.92 | 50.21 ± 11.91 | −6.8 | 0.001 | | Complete response | 22 (38.6%) | 35 (61.4%) | 5.3 | 0.028 | 33 (57.9%) | 24 (42.1%) | 6.7 | 0.01 | | Relapse/refractory | 19 (50%) | 19 (50%) | 0.8 | 0.3 | 18 (47.4%) | 20 (52.6%) | 0.3 | 0.6 |
|
|
